Charles River Laboratories
620 hedge funds and large institutions have $10.3B invested in Charles River Laboratories in 2023 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 243 increasing their positions, 214 reducing their positions, and 68 closing their positions.
28% more call options, than puts
Call options by funds: $48.9M | Put options by funds: $38.1M
14% more repeat investments, than reductions
Existing positions increased: 243 | Existing positions reduced: 214
12% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 68
2.42% more ownership
Funds ownership: 97.73% → 100.16% (+2.4%)
5% less capital invested
Capital invested by funds: $10.8B → $10.3B (-$493M)
1% less funds holding
Funds holding: 627 → 620 (-7)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$148M |
| 2 |
SCA
Southpoint Capital Advisors
New York
|
+$90.7M |
| 3 |
FAM
Fred Alger Management
New York
|
+$53.8M |
| 4 |
CI Investments Inc
Toronto,
Ontario, Canada
|
+$49.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$74.3M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$67.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$45.9M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$45.4M |
| 5 |
BlackRock
New York
|
-$38.8M |
CRL Hedge Fund Activity: Q1 2023 in Review
620 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2023, worth a combined $10.3B — down 4.6% from $10.8B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new CRL positions and 68 closed out — a net gain of 8 holders — while 243 added to existing stakes and 214 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $148M. The largest seller was Millennium Management, cutting an estimated $74.3M.
- 620 institutional investors held Charles River Laboratories (CRL) as of Q1 2023, down from 627 in Q4 2022.
- Funds reported $10.3B of Charles River Laboratories stock for Q1 2023, down 4.6% quarter-over-quarter.
- 76 funds opened new Charles River Laboratories positions in Q1 2023 and 68 closed out, a net change of +8 holders.
- The largest Charles River Laboratories buyer in Q1 2023 was T. Rowe Price Associates, an estimated $148M added.
- The largest Charles River Laboratories seller in Q1 2023 was Millennium Management, an estimated $74.3M sold.
Based on aggregated 13F filings for Q1 2023.